Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 20/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1876350 | 0.84 | ADORA1 (0.83) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL12080712 | 0.83 | ADORA1 (0.82) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL1867558 | 0.77 | ADORA1 (0.54) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL1724549 | 0.76 | ADORA1 (0.53) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL30891834 | 0.76 | ADORA1 (0.53) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL12080727 | 0.76 | ADORA1 (0.54) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL1893989 | 0.75 | ADORA1 (0.83) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL1867189 | 0.75 | ADORA1 (1.00) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL1867327 | 0.74 | ADORA1 (0.98) | ADORA1ADORA3ADORA2BADORA2A | |
| SCHEMBL12080280 | 0.74 | ADORA1 (0.83) | ADORA1ADORA3ADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859566-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2014-10-14 | — | — | US | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA3 3/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.